Publications by authors named "Xin-Bin Pan"
To compare the survival outcomes of patients with stage T2N0M0 esophageal cancer treated with surgery alone versus those treated with neoadjuvant chemoradiotherapy followed by surgery. Patients with stage T2N0M0 esophageal cancer, who either underwent surgery alone or received neoadjuvant chemoradiotherapy followed by surgery, were extracted from the Surveillance, Epidemiology, and End Results database covering the period from 2000 to 2020. Cancer-specific survival (CSS) and overall survival (OS) between the two treatment groups were compared.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how the number of examined lymph nodes (ELNs) affects survival outcomes in surgical patients with stage T1-2N0M0 small cell lung cancer (SCLC).
- Using data from the Surveillance, Epidemiology, and End Results database, researchers found that a threshold of 7 ELNs significantly predicts better cancer-specific survival (CSS) and overall survival (OS).
- Patients with fewer than 7 ELNs had substantially lower median CSS and OS compared to those with 7 or more, highlighting ELN count as an important factor in postoperative prognosis for this patient group.
Article Synopsis
- This study compares the effectiveness of neoadjuvant chemotherapy (NACT) followed by surgery versus concurrent chemoradiotherapy (CCRT) for treating stage IIB cervical squamous cell carcinoma (CSCC).
- Researchers analyzed data from 257 patients treated at Guangxi Medical University Cancer Hospital and assessed overall survival, locoregional-free survival, and distant metastasis-free survival between the two treatment approaches.
- Results indicated that the NACT followed by surgery group had significantly lower survival rates compared to the CCRT group, suggesting that CCRT may be a more effective treatment option for these patients.
Objective: We investigated the efficacy of metastatic lesion radiotherapy (MLRT) in patients with metastatic nasopharyngeal carcinoma (mNPC).
Materials And Methods: Patients with mNPC from three institutions were included in this study. Propensity score matching (PSM) was employed to ensure comparability between patient groups.
Article Synopsis
- The study evaluates different treatment methods for stage T4b esophageal cancer by analyzing patient data from 2000 to 2020.
- A total of 482 patients were included, with various treatments showing differing cancer-specific survival (CSS) and overall survival (OS) rates, notably better outcomes for those who underwent surgery.
- The findings indicate that esophagectomy leads to significantly improved survival compared to chemoradiotherapy in these patients.
Article Synopsis
- A study analyzed survival outcomes in 445 patients with pT3N0M0 esophageal cancer who underwent surgery without prior chemoradiotherapy, using data from 2000 to 2020.
- Among patients with squamous cell carcinoma, various adjuvant treatments (chemoradiotherapy, chemotherapy, and radiotherapy) did not show significant survival benefits compared to surgery alone.
- Conversely, for those with adenocarcinoma, both adjuvant chemoradiotherapy and chemotherapy significantly improved overall survival compared to surgery alone, highlighting the varying effectiveness of treatments based on cancer type.
Article Synopsis
- The study assessed the effectiveness of combining immune checkpoint inhibitors (ICIs) with concurrent chemoradiotherapy (CCRT) versus using CCRT alone for treating locally advanced esophageal squamous cell carcinoma.
- A total of 101 patients participated, with results showing that while the combination therapy had a higher complete response rate (11.6% vs. 1.7%), it did not significantly improve progression-free survival or overall survival compared to CCRT alone.
- The findings also revealed differences in side effects, with CCRT alone causing more leukopenia, while the combination therapy led to a higher incidence of pneumonitis, highlighting the need for more research on these treatment options.
Article Synopsis
- * Analysis of data from the SEER database identified a lymph node ratio (LNR) of 0.29 as a critical threshold, indicating worse cancer-specific survival (CSS) and overall survival (OS) for patients with higher ratios.
- * Results showed that postoperative radiotherapy did not improve survival outcomes in high-risk patients (LNR ≥ 0.29), suggesting it may not be necessary for this group and highlighting the need for further research on alternative treatments.
Article Synopsis
- - The study aimed to evaluate various treatment approaches and survival outcomes for patients with stage T1-2N0M0 small cell lung cancer who had surgery, using data from 2000 to 2020.
- - A total of 190 patients were analyzed, with treatment options including surgery alone, surgery with chemotherapy, and surgery with chemoradiotherapy, finding that surgery + chemotherapy significantly improved overall survival (OS) compared to surgery alone.
- - The results showed median cancer-specific survival (CSS) was undetermined for surgery alone, while it was 123 and 113 months for the other groups, and highlighted that while chemotherapy benefited OS, adding radiotherapy did not enhance survival outcomes.
Purpose: To assess survival of treatment patterns based on concurrent chemoradiotherapy (CCRT) in patients with stage IIB cervical squamous cell carcinoma (CSCC).
Materials And Methods: Patients with stage IIB CSCC receiving CCRT were investigated from June 2012 to June 2019 in Guangxi Medical University Cancer Hospital. Baseline characteristics and treatment patterns were described.
Article Synopsis
- A study was conducted to analyze treatment patterns and survival results for patients with unresectable Stage III EGFR-mutated non-small cell lung cancer (NSCLC) between 2012 and 2022.
- Out of 88 patients, most were treated with tyrosine kinase inhibitors (TKI), and comparisons showed that adding chemotherapy to TKI did not improve progression-free or overall survival outcomes.
- Ultimately, the findings indicated that combining chemotherapy with TKI did not provide better survival results than using TKI alone for these patients.
Article Synopsis
- - The study evaluated the effectiveness of lymph node ratio (LNR) versus pN in predicting outcomes for patients with non-small cell lung cancer (NSCLC) who had surgery, using data from 2004 to 2015.
- - It identified LNR cut-off values of 0.19 and 0.73, revealing that patients with lower LNR (LNR1) had significantly longer cancer-specific survival (CSS) and overall survival (OS) compared to those with higher LNR values (LNR2 and LNR3).
- - The research concluded that a revised pN classification that includes LNR offers better predictive accuracy for CSS and OS, suggesting that LNR may be a more effective tool for
Article Synopsis
- This study investigates the effectiveness of combining first-line immunotherapy with chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC), focusing on those with and without brain metastases.
- A review of seven randomized controlled trials found that patients without brain metastases experienced significant improvements in both progression-free survival (PFS) and overall survival (OS) when receiving the combination treatment compared to chemotherapy alone.
- In contrast, patients with brain metastases showed no significant benefits in PFS or OS from the addition of immunotherapy to their chemotherapy regimen.
Article Synopsis
- Esophageal cancer is the sixth most common cancer globally, with about 50% of patients having advanced stages of the disease.
- Standard treatment for resectable cases involves neoadjuvant chemoradiotherapy followed by surgery, but many patients don't achieve complete responses and often have poor outcomes.
- The CheckMate 577 trial shows that nivolumab adjuvant therapy can improve disease-free survival for those not achieving a complete response, yet there are still unresolved clinical questions from the study's subgroup analyses that this review aims to address.
Article Synopsis
- - The study investigates how the presence of liver metastases affects the survival outcomes of first-line immunotherapy combined with chemotherapy in patients with extensive stage small cell lung cancer (ES-SCLC).
- - Out of six analyzed trials involving 3,501 patients, results showed that while immunotherapy improved progression-free survival (PFS) and overall survival (OS) in patients without liver metastases, it did not provide significant benefits for those with liver metastases.
- - The conclusion emphasizes that first-line immunotherapy plus chemotherapy is beneficial for ES-SCLC patients without liver metastases, but offers little advantage for those with liver metastases.
Article Synopsis
- - The study aimed to compare survival rates between unresectable stage III and stage IV patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with first-line EGFR-TKI.
- - The analysis included 558 patients, revealing that stage III patients had better progression-free survival (PFS) but similar overall survival (OS) compared to stage IV patients both before and after propensity score matching (PSM).
- - Ultimately, the research concluded that while stage III patients had a higher median PFS, there was no significant difference in OS between the two stages when receiving EGFR-TKI treatment.
Purpose: This study explored the relationship between the prognostic nutritional index (PNI) and overall survival rate (OS) in patients with nasopharyngeal carcinoma (NPC), and established and validated an effective nomogram to predict clinical outcomes.
Methods: This study included 618 patients newly diagnosed with locoregionally advanced NPC. They were divided into training and validation cohorts at a ratio of 2:1 based on random numbers.
To identify risk factors of secondary cancer in nasopharyngeal carcinoma (NPC) patients after radiotherapy. The data of NPC patients with secondary cancer were extracted from the Surveillance, Epidemiology, and End Results database from 2004 to 2016. Univariate and multivariate logistic regression analysis was performed to identify risk factors of secondary cancer.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to evaluate the effectiveness of combining EGFR-TKIs with antiangiogenic agents in treating non-small cell lung cancer patients with two specific genetic mutations: exon 19 deletion and exon 21 Leu858 Arg.
- - Researchers conducted a systematic review of five high-quality randomized control trials involving 1533 patients, analyzing their progression-free survival (PFS) with the combination treatment versus EGFR-TKI alone.
- - Results showed that the combination treatment improved PFS similarly for both mutation groups, indicating no significant difference in outcomes based on the type of genetic mutation (P=0.07, p=0.94).
Article Synopsis
- - The study investigated the impact of postoperative radiotherapy (PORT) on patients with pIIIA-N2 non-small cell lung cancer following surgery and chemotherapy.
- - Researchers analyzed data from three high-quality randomized control trials involving 902 patients, comparing the effects of PORT with observation.
- - Findings indicated that while PORT significantly reduced local recurrence rates, it had no significant effect on disease-free survival (DFS) or overall survival (OS).
A novel risk signature with 6 RNA binding proteins for prognosis prediction in patients with glioblastoma.
Medicine (Baltimore)
December 2021
Recent studies suggested that RNA binding proteins (RBPs) were related to the tumorigenesis and progression of glioma. This study was conducted to identify prognostic RBPs of glioblastoma (GBM) and construct an RBP signature to predict the prognosis of GBM.Univariate Cox regression analysis was carried out to identify the RBPs associated with overall survival of GBM in the The Cancer Genome Atlas (TCGA), GSE16011, and Repository for Molecular Brain Neoplasia data (Rembrandt) datasets, respectively.
View Article and Find Full Text PDFPurpose: To identify whether chemoradiotherapy improves survival of stage I nasopharyngeal carcinoma (NPC).
Materials And Methods: NPC patients were extracted from the Surveillance, Epidemiology, and End Results database between 2010 and 2015. Pathologically confirmed stage T1N0M0 (the 7 edition AJCC) were investigated.
Article Synopsis
- - The study evaluated the impact of lymph nodal diameter on the staging of nasopharyngeal carcinoma (NPC) according to the 8th edition American Joint Committee on Cancer guidelines, using data from 2004 to 2016.
- - Patients were categorized into three groups based on nodal diameter: ≤3 cm, >3-6 cm, and >6 cm, with survival outcomes analyzed using 5-year overall survival (OS) and cancer-specific survival (CSS).
- - Results showed significant differences in survival rates for patients with lymph nodes >6 cm compared to those in the ≤3 cm and >3-6 cm groups, supporting the classification of >6 cm nodal diameter as stage N3 in
Purposes: To evaluate retropharyngeal lymph node metastasis on N stage of nasopharyngeal carcinoma (NPC).
Methods: NPC patients were extracted from the Surveillance, Epidemiology, and End Results database between 2004 and 2016. Pathologically confirmed patients with complete data of retropharyngeal lymph node metastasis were investigated.
Identification of prognostic tumor-infiltrating immune cells in endometrial adenocarcinoma.
Medicine (Baltimore)
May 2021
Article Synopsis
- The study aims to identify immune cells within endometrial adenocarcinoma tumors that could indicate patient prognosis.
- Using gene expression data from TCGA and the CIBERSORT algorithm, researchers found 22 different types of tumor-infiltrating immune cells.
- Notably, an increase in M0 macrophages was linked to better prognosis (P = .038), while higher levels of CD8 T cells correlated with worse outcomes (P = .049).